ATE293169T1 - Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen - Google Patents

Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen

Info

Publication number
ATE293169T1
ATE293169T1 AT02729440T AT02729440T ATE293169T1 AT E293169 T1 ATE293169 T1 AT E293169T1 AT 02729440 T AT02729440 T AT 02729440T AT 02729440 T AT02729440 T AT 02729440T AT E293169 T1 ATE293169 T1 AT E293169T1
Authority
AT
Austria
Prior art keywords
latency
pharmaceutically active
fusion protein
nucleic acid
construct
Prior art date
Application number
AT02729440T
Other languages
English (en)
Inventor
Yuti Chernajovsky
Hanna Stina Dreja
Gillian Adams
Original Assignee
Queen Mary & Westfield College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary & Westfield College filed Critical Queen Mary & Westfield College
Application granted granted Critical
Publication of ATE293169T1 publication Critical patent/ATE293169T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02729440T 2001-01-09 2002-01-09 Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen ATE293169T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0100551.1A GB0100551D0 (en) 2001-01-09 2001-01-09 Protein
US09/756,283 US6942853B2 (en) 2001-01-09 2001-01-09 Latent fusion protein
PCT/GB2002/000068 WO2002055098A2 (en) 2001-01-09 2002-01-09 Latency associated peptide for providing latency to pharmaceutically active proteins

Publications (1)

Publication Number Publication Date
ATE293169T1 true ATE293169T1 (de) 2005-04-15

Family

ID=26245544

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02729440T ATE293169T1 (de) 2001-01-09 2002-01-09 Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen

Country Status (10)

Country Link
US (1) US6942853B2 (de)
EP (1) EP1349944B1 (de)
JP (1) JP4201253B2 (de)
AT (1) ATE293169T1 (de)
AU (1) AU2002219345B2 (de)
DE (1) DE60203692T2 (de)
DK (1) DK1349944T3 (de)
ES (1) ES2240740T3 (de)
GB (1) GB0100551D0 (de)
WO (1) WO2002055098A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141392B2 (en) * 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
JP2006503545A (ja) * 2002-02-14 2006-02-02 ラター， ウィリアム ジェイ． 処置される宿主における切断についてのキメラ分子
JP2009510166A (ja) * 2005-10-04 2009-03-12 グリーンビル ホスピタル システム 潜伏性プロサイトトキシンおよびそれらの用途
DE102006009324A1 (de) 2006-03-01 2007-09-06 Dr.Ing.H.C. F. Porsche Ag Verfahren und Steuergerät zur Steuerung eines variablen Turbolader-Turbinenströmungsquerschnitts
EP2572734B1 (de) 2006-10-31 2016-04-06 East Carolina University Cytokinbasierte Fusionsproteine zur Behandlung von Immunstörungen
GB0724556D0 (en) * 2007-12-17 2008-01-30 Queen Mary & Westfield College LAtency associated protein construct with aggrecanase sensitive cleavage site
FR2932190A1 (fr) * 2008-06-10 2009-12-11 Commissariat Energie Atomique Peptides cycliques fluorescents, procedes de preparation de ceux-ci et utilisation de ces peptides pour mesurer l'activite enzymatique d'une enzyme protease
EP3348275A3 (de) 2009-03-31 2018-10-24 East Carolina University Cytokine und neuroantigene zur behandlung von immunerkrankungen
GB0911365D0 (en) 2009-06-30 2009-08-12 Bioceramic Therapeutics Ltd Multicomponent glasses for use as coatings and in personal care products
WO2011123683A2 (en) * 2010-04-02 2011-10-06 University Of Rochester Protease activated cytokines
EP2878308B1 (de) * 2013-12-02 2018-10-31 Thomas Harder Mittel und Verfahren zur Unterdrückung der T-Zell-Aktivierung
GB201411506D0 (en) 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
JP6516235B2 (ja) * 2014-10-31 2019-05-22 国立大学法人富山大学 キメラタンパク質及びそれを用いたミクログリア活性阻害剤
CA3100005A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
WO2019222295A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
MX2021003543A (es) 2018-09-27 2021-06-23 Xilio Dev Inc Polipeptidos de citocinas enmascaradas.
ES2780274A1 (es) 2019-02-15 2020-08-24 Consejo Superior De Investig Científicas (Csic) Cortistatina o un análogo de la misma como agente farmacéuticamente activo en forma latente
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
AU2020291012A1 (en) 2019-06-12 2021-12-16 AskGene Pharma, Inc. Novel IL-15 prodrugs and methods of use thereof
MX2022005666A (es) * 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
GB202004679D0 (en) 2020-03-31 2020-05-13 Stealthyx Therapeutics Ltd Modified latercy associated protein construct
MX2022012592A (es) 2020-04-10 2022-12-07 Cytomx Therapeutics Inc Construcciones de citocinas activables y composiciones y metodos relacionados.
TW202304958A (zh) 2021-03-16 2023-02-01 美商Ｃｙｔｏｍｘ生物製藥公司 經遮蔽之可活化之細胞介素構築體及相關之組成物及方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284763A (en) * 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
CA2003886A1 (en) 1988-12-16 1990-06-16 Anthony F. Purchio Cloning and expression of simian transforming growth factor-beta 1
DE69024369T2 (de) 1989-11-22 1996-06-13 Genentech, Inc., South San Francisco, Calif. Latenz assoziierte peptide und deren verwendung
US5697901A (en) 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
ES2213745T3 (es) 1993-05-12 2004-09-01 Genetics Institute, Llc Composiciones de bmp-11.
DE69528128T2 (de) 1994-06-10 2003-03-13 United States Surgical Corp., Norwalk Rekombinante Chimäre Proteine und Verfahren zur deren Verwendung
US5800811A (en) * 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
JPH11513249A (ja) * 1995-09-27 1999-11-16 メディカル・リサーチ・カウンシル プロテアーゼにより開裂可能なタンパク質を組込んだ組換えウイルス
DE19701141C1 (de) 1997-01-16 1998-04-09 Hoechst Ag Genkonstrukte für durch Proteasen aktivierbare Wirksubstanzen
US6593132B1 (en) * 1997-04-30 2003-07-15 Twinstrand Therapeutics Inc. Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
GB2324960A (en) 1997-05-09 1998-11-11 Univ Manchester Delivery of naked DNA for wound healing
JP3762222B2 (ja) 1998-10-07 2006-04-05 ストライカー・コーポレーション 改変型ＴＧＦ−βスーパーファミリータンパク質
EP1322785A4 (de) * 2000-09-11 2005-11-09 Univ Columbia Kombinatorische fluoreszenzenergietransfer-tags und deren verwendungen

Also Published As

Publication number Publication date
GB0100551D0 (en) 2001-02-21
WO2002055098A3 (en) 2002-11-21
US20020151478A1 (en) 2002-10-17
EP1349944A2 (de) 2003-10-08
JP2004520031A (ja) 2004-07-08
DE60203692T2 (de) 2006-03-02
EP1349944B1 (de) 2005-04-13
AU2002219345B2 (en) 2006-03-16
JP4201253B2 (ja) 2008-12-24
WO2002055098A2 (en) 2002-07-18
US6942853B2 (en) 2005-09-13
DK1349944T3 (da) 2005-07-25
ES2240740T3 (es) 2005-10-16
DE60203692D1 (de) 2005-05-19

Similar Documents

Publication Publication Date Title
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
ATE500323T1 (de) Subtilisin-variante
EA200901129A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
AR008727A1 (es) COMPOSICIONES Y PROTEINAS DE FUSIoN QUE COMPRENDEN UN POLIPEPTIDO QUE COMPRENDE UNA PORCION INMUNOGENICA DE UNA PROTEINA DE PROSTATA O SU VARIANTE, Y USOS DE LAS MISMAS PARA PREPARAR UN MEDICAMENTO
YU8997A (sh) Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži
WO2002014358A3 (en) Novel secreted proteins and their uses
DK1904529T3 (da) Anvendelse af Stefin A som et scaffoldprotein
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
WO2004054607A3 (de) Stabile therapeutische proteine
AU2003222717A8 (en) Streptavidin-binding peptide
DE69941433D1 (de) Von protease typ ii spaltbares peptid
WO2002022662A3 (en) Insect inhibitory bacillus thuringiensis proteins, fusions, and methods of use therefor
WO2003082897A3 (en) Synthetic active peptide fragments
WO2002016578A3 (en) Secreted proteins and methods of using same
ATE278011T1 (de) Human dnase ii
DE60015559D1 (de) Sentrin-spezifische menschliche protease senp1
FR2813606B1 (fr) Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
WO2004053117A3 (en) Serine protease
ATE427355T1 (de) Menschliche alpha2-delta4-calciumkanal- untereinheit codierende cdna
TH62241A (th) ไบคูนินของคน
DE60129228D1 (de) Humane 7-transmembranproteine und dafür codierende polynukleotide
WO2002000709A3 (en) Cerebellin homologous polypeptides and therapeutic uses thereof
WO2003031463A3 (en) 14081, a human trypsin-like serine protease family member and uses therefor
WO2002068464A3 (de) Fusionsprotein zum blocken des hiv nef-proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties